Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence

Steven Shoptaw, Alice Huber, James Peck, Xiaowei Yang, Juanmei Liu, Dang Jeff Dang, John Roll, Benjamin Shapiro, Erin Rotheram-Fuller, Walter Ling

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalDrug and Alcohol Dependence
Volume85
Issue number1
DOIs
StatePublished - Oct 15 2006
Externally publishedYes

Fingerprint

Sertraline
Methamphetamine
contingency
Randomized Controlled Trials
Placebos
management
Therapeutics
relapse
Preclinical Drug Evaluations
mood
Public health
Secondary Prevention
drug use
Visual Analog Scale
Pharmaceutical Preparations
medication
Psychiatry
public health
Length of Stay
Screening

Keywords

  • Contingency management
  • Drug abuse
  • Medications
  • Methamphetamine
  • Sertraline

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. / Shoptaw, Steven; Huber, Alice; Peck, James; Yang, Xiaowei; Liu, Juanmei; Jeff Dang, Dang; Roll, John; Shapiro, Benjamin; Rotheram-Fuller, Erin; Ling, Walter.

In: Drug and Alcohol Dependence, Vol. 85, No. 1, 15.10.2006, p. 12-18.

Research output: Contribution to journalArticle

Shoptaw, Steven ; Huber, Alice ; Peck, James ; Yang, Xiaowei ; Liu, Juanmei ; Jeff Dang, Dang ; Roll, John ; Shapiro, Benjamin ; Rotheram-Fuller, Erin ; Ling, Walter. / Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. In: Drug and Alcohol Dependence. 2006 ; Vol. 85, No. 1. pp. 12-18.
@article{878803afc3b64f168a98568b460af2c8,
title = "Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence",
abstract = "Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.",
keywords = "Contingency management, Drug abuse, Medications, Methamphetamine, Sertraline",
author = "Steven Shoptaw and Alice Huber and James Peck and Xiaowei Yang and Juanmei Liu and {Jeff Dang}, Dang and John Roll and Benjamin Shapiro and Erin Rotheram-Fuller and Walter Ling",
year = "2006",
month = "10",
day = "15",
doi = "10.1016/j.drugalcdep.2006.03.005",
language = "English (US)",
volume = "85",
pages = "12--18",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence

AU - Shoptaw, Steven

AU - Huber, Alice

AU - Peck, James

AU - Yang, Xiaowei

AU - Liu, Juanmei

AU - Jeff Dang, Dang

AU - Roll, John

AU - Shapiro, Benjamin

AU - Rotheram-Fuller, Erin

AU - Ling, Walter

PY - 2006/10/15

Y1 - 2006/10/15

N2 - Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.

AB - Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.

KW - Contingency management

KW - Drug abuse

KW - Medications

KW - Methamphetamine

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=33748320854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748320854&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2006.03.005

DO - 10.1016/j.drugalcdep.2006.03.005

M3 - Article

VL - 85

SP - 12

EP - 18

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -